Regeneron Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Regeneron Pharmaceuticals's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8% to $13,117,200,000. Profit margin reached 30%. Total operating expenses were $7,254,300,000.
Profit Margin
| 2014 | 2.81B | 348.07M | 12.34% |
|---|---|---|---|
| 2015 | 4.10B | 636.05M | 15.5% |
| 2016 | 4.86B | 895.52M | 18.42% |
| 2017 | 5.87B | 1.19B | 20.41% |
| 2018 | 6.71B | 2.44B | 36.42% |
| 2019 | 7.86B | 2.11B | 26.91% |
| 2020 | 8.49B | 3.51B | 41.35% |
| 2021 | 16.07B | 8.07B | 50.25% |
| 2022 | 12.17B | 4.33B | 35.64% |
| 2023 | 13.11B | 3.95B | 30.14% |
REGN Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 13.11B | 12.17B | 16.07B | 8.49B | 7.86B | 6.71B | 5.87B | 4.86B | 4.10B | 2.81B |
Cost of revenue | 1.81B | 1.56B | 2.43B | 1.11B | 782.2M | 434.1M | 397.06M | 299.69M | 392.70M | 205.01M |
Gross profit | 11.30B | 10.61B | 13.63B | 7.37B | 7.08B | 6.27B | 5.47B | 4.56B | 3.71B | 2.61B |
Operating exp. | ||||||||||
Research and development | 4.43B | 3.59B | 2.90B | 2.73B | 3.03B | 2.18B | 2.07B | 2.05B | 1.62B | 1.27B |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 7.25B | 5.61B | 4.68B | 3.80B | 4.87B | 3.74B | 3.39B | 3.22B | 2.45B | 1.77B |
Operating income | 4.04B | 4.73B | 8.94B | 3.57B | 2.20B | 2.53B | 2.07B | 1.33B | 1.25B | 838.43M |
Other income (expenses), net | 152.2M | 119.9M | 379M | 233.8M | 219.3M | 19.1M | -1.08M | -926K | -26.81M | -62.68M |
Income before tax | 4.19B | 4.85B | 9.32B | 3.81B | 2.42B | 2.55B | 2.07B | 1.32B | 1.22B | 775.74M |
Income tax expense | 245.7M | 520.4M | 1.25B | 297.2M | 313.3M | 109.1M | 880M | 434.29M | 589.04M | 427.67M |
Net income | 3.95B | 4.33B | 8.07B | 3.51B | 2.11B | 2.44B | 1.19B | 895.52M | 636.05M | 348.07M |
Earnings per share | ||||||||||
Basic EPS | 37.05 | 40.51 | 76.4 | 32.65 | 19.38 | 21.29 | 11.27 | 8.55 | 6.17 | 3.36 |
Diluted EPS | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 | 21.29 | 10.34 | 7.7 | 5.52 | 2.98 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |